|
1. A method of treating a patient suffering from familial hypercholesterolemia (FH), wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy, the method comprising treating the patient with a combination of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and an inhibitor of angiopoietin-like protein 3 (ANGPTL3), wherein the PSCK9 inhibitor is an antibody, or an antigen-binding fragment thereof, that binds specifically to PCSK9, wherein the antibody or antigen-binding fragment thereof that binds specifically to PCSK9 comprises the complementary determining regions (CDRs) of a heavy chain variable (HCVR) having the amino acid sequence of SEQ ID NO: 12 and the CDRs of a light chain variable region (LCVR) of SEQ ID NO: 17, wherein the ANGPTL3 inhibitor is an antibody, or an antigen-binding fragment thereof, that binds specifically to ANGPTL3, wherein the antibody or antigen-binding fragment thereof that binds specifically to ANGPTL3 comprises the complementary determining regions (CDRs) of a heavy chain variable (HCVR) having the amino acid sequence of SEQ ID NO: 2 and the CDRs of a light chain variable region (LCVR) of SEQ ID NO: 3, wherein the patient who is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy exhibits (i) an LDL-C level of greater than or equal to 100 mg/dL despite undergoing the standard lipid modifying therapy or (ii) a reduction in LDL-C or non-HDL-C of less than 50% from baseline despite undergoing the standard lipid modifying therapy.
|